isoproterenol has been researched along with Dyslipidemias in 6 studies
Isoproterenol: Isopropyl analog of EPINEPHRINE; beta-sympathomimetic that acts on the heart, bronchi, skeletal muscle, alimentary tract, etc. It is used mainly as bronchodilator and heart stimulant.
isoprenaline : A secondary amino compound that is noradrenaline in which one of the hydrogens attached to the nitrogen is replaced by an isopropyl group. A sympathomimetic acting almost exclusively on beta-adrenergic receptors, it is used (mainly as the hydrochloride salt) as a bronghodilator and heart stimulant for the management of a variety of cardiac disorders.
Dyslipidemias: Abnormalities in the serum levels of LIPIDS, including overproduction or deficiency. Abnormal serum lipid profiles may include high total CHOLESTEROL, high TRIGLYCERIDES, low HIGH DENSITY LIPOPROTEIN CHOLESTEROL, and elevated LOW DENSITY LIPOPROTEIN CHOLESTEROL.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study evaluates the protective effects of 7-hydroxycoumarin (7-HC) on dyslipidemia and cardiac hypertrophy in isoproterenol (ISO) induced myocardial infarction (MI) in rats." | 7.83 | Protective Effects of 7-Hydroxycoumarin on Dyslipidemia and Cardiac Hypertrophy in Isoproterenol-Induced Myocardial Infarction in Rats. ( Jagadeesh, GS; Nagoor Meeran, MF; Selvaraj, P, 2016) |
| " This study aims to evaluate the protective effects of sinapic acid on cardiac hypertrophy, dyslipidaemia and alterations in lipoproteins and electrocardiogram in isoproterenol-induced myocardial infarcted rats." | 7.79 | Protective effects of sinapic acid on cardiac hypertrophy, dyslipidaemia and altered electrocardiogram in isoproterenol-induced myocardial infarcted rats. ( Mainzen Prince, PS; Roy, SJ, 2013) |
| "Although spironolactone and telmisartan are reported to reduce the risk of morbidity and death, direct studies on their effects on isoproterenol-induced cardiac hypertrophy are scanty." | 7.78 | Beneficial role of spironolactone, telmisartan and their combination on isoproterenol-induced cardiac hypertrophy. ( Goyal, BR; Mehta, AA, 2012) |
| "This study evaluates the protective effects of 7-hydroxycoumarin (7-HC) on dyslipidemia and cardiac hypertrophy in isoproterenol (ISO) induced myocardial infarction (MI) in rats." | 3.83 | Protective Effects of 7-Hydroxycoumarin on Dyslipidemia and Cardiac Hypertrophy in Isoproterenol-Induced Myocardial Infarction in Rats. ( Jagadeesh, GS; Nagoor Meeran, MF; Selvaraj, P, 2016) |
| " This study aims to evaluate the protective effects of sinapic acid on cardiac hypertrophy, dyslipidaemia and alterations in lipoproteins and electrocardiogram in isoproterenol-induced myocardial infarcted rats." | 3.79 | Protective effects of sinapic acid on cardiac hypertrophy, dyslipidaemia and altered electrocardiogram in isoproterenol-induced myocardial infarcted rats. ( Mainzen Prince, PS; Roy, SJ, 2013) |
| "Although spironolactone and telmisartan are reported to reduce the risk of morbidity and death, direct studies on their effects on isoproterenol-induced cardiac hypertrophy are scanty." | 3.78 | Beneficial role of spironolactone, telmisartan and their combination on isoproterenol-induced cardiac hypertrophy. ( Goyal, BR; Mehta, AA, 2012) |
| "Dyslipidemia is an important factor in MetS and is related to atrial fibrillation (AF)." | 1.43 | VLDL from Metabolic Syndrome Individuals Enhanced Lipid Accumulation in Atria with Association of Susceptibility to Atrial Fibrillation. ( Chen, CH; Chu, CS; Hsiao, YL; Ke, LY; Lai, WT; Lee, HC; Lin, HT; Sheu, SH; Shin, SJ; Wei, C; Wu, BN, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Al-Rasheed, NM | 2 |
| Attia, HA | 1 |
| Mohamed, RA | 1 |
| Al-Amin, MA | 1 |
| Lee, HC | 1 |
| Lin, HT | 1 |
| Ke, LY | 1 |
| Wei, C | 1 |
| Hsiao, YL | 1 |
| Chu, CS | 1 |
| Lai, WT | 1 |
| Shin, SJ | 1 |
| Chen, CH | 1 |
| Sheu, SH | 1 |
| Wu, BN | 1 |
| Jagadeesh, GS | 1 |
| Nagoor Meeran, MF | 1 |
| Selvaraj, P | 1 |
| Selenscig, D | 1 |
| Rossi, A | 1 |
| Chicco, A | 1 |
| Lombardo, YB | 1 |
| Goyal, BR | 1 |
| Mehta, AA | 1 |
| Roy, SJ | 1 |
| Mainzen Prince, PS | 1 |
6 other studies available for isoproterenol and Dyslipidemias
| Article | Year |
|---|---|
Preventive effects of selenium yeast, chromium picolinate, zinc sulfate and their combination on oxidative stress, inflammation, impaired angiogenesis and atherogenesis in myocardial infarction in rats.
Topics: Animals; Atherosclerosis; Cardiotonic Agents; Drug Therapy, Combination; Dyslipidemias; Inflammation | 2013 |
VLDL from Metabolic Syndrome Individuals Enhanced Lipid Accumulation in Atria with Association of Susceptibility to Atrial Fibrillation.
Topics: Adult; Animals; Apoptosis; Atrial Fibrillation; Cardiac Output; Cardiotonic Agents; Diastole; Diseas | 2016 |
Protective Effects of 7-Hydroxycoumarin on Dyslipidemia and Cardiac Hypertrophy in Isoproterenol-Induced Myocardial Infarction in Rats.
Topics: Adrenergic beta-Agonists; Animals; Cardiomegaly; Dyslipidemias; Hydroxymethylglutaryl CoA Reductases | 2016 |
Increased leptin storage with altered leptin secretion from adipocytes of rats with sucrose-induced dyslipidemia and insulin resistance: effect of dietary fish oil.
Topics: Adipocytes; Adipose Tissue, White; Adrenergic beta-Agonists; Animals; Body Weight; Cell Count; Cell | 2010 |
Beneficial role of spironolactone, telmisartan and their combination on isoproterenol-induced cardiac hypertrophy.
Topics: Adrenergic beta-Agonists; Algorithms; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazol | 2012 |
Protective effects of sinapic acid on cardiac hypertrophy, dyslipidaemia and altered electrocardiogram in isoproterenol-induced myocardial infarcted rats.
Topics: Animals; Antioxidants; Cardiomegaly; Coumaric Acids; Dyslipidemias; Electrocardiography; Hydroxymeth | 2013 |